SAGE forges agreement with the International Headache Society

NewsGuard 100/100 Score

SAGE, the world's leading independent academic and professional publisher is delighted to announce a new agreement with the International Headache Society (IHS) to publish their official journal, Cephalalgia.

Now in its 29th volume, Cephalalgia provides an international forum for original research papers, review articles and short communications on all aspects of headache. Publishing monthly, readers receive timely cutting edge communications on clinical and basic research, as well as news on events within the headache community.

This transition is the latest in a number of high profile journals moving to SAGE in 2010. SAGE is the world's fifth largest journals publisher, with more than 520 titles across many disciplines in, science, technology and medicine, humanities and social sciences. Cephalalgia joins a growing collection of Neuroscience and Neurology journals, including The Neuroscientist; Neurorehabilitation & Neural Repair, Multiple Sclerosis, Therapeutic Advances in Neurological Disorders and the Journal of Child Neurology.

"The International Headache Society is delighted to partner with SAGE," said Anne MacGregor, IHS Treasurer. "Sharing similar missions, SAGE is the 'natural' home for IHS. We have already evidenced the responsive and flexible approach provided by their integrated team and we look forward to an exciting future for the journal."

"We are thrilled to be entering a new partnership with the IHS, and to be working with them from 2010 to achieve the very best results for the society and their prestigious journal," said Tessa Picknett, Associate Director and STM Publisher at SAGE. "As one of the few remaining independent academic publishers, SAGE offers a unique proposition to societies looking for a dynamic, proactive and innovative publishing partner. We pride ourselves on combining global publishing expertise with a personal and tailored service that we believe will actively support the continued growth and development of Cephalalgia."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Nigeria first to rollout new Men5CV vaccine against meningitis